The cumulative incidence plots according to Gray method showed that in the breast cancer patients with stage I-III or with stage I-III and HoR+/HER2- subtype, patients with young age (less than 40 years) had more BCSD compared to the patients with 41–60 years (both with P < 0.001). Here, ERBB2 is linked to breast cancer.